Medicare Enrolled
Dr. Dileep Puppala, M.D.
Critical Care Medicine · Houston, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Puppala from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Puppala?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Puppala
Dr. Dileep Puppala is a critical care medicine specialist in Houston, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Puppala performed 16,201 Medicare services across 2,015 unique beneficiaries.
Between the years covered by Open Payments, Dr. Puppala received a total of $103,802 from 69 pharmaceutical and/or device companies across 1095 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in critical care medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Puppala is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 1% volume in TX
$103,802 industry payments
Medicare Practice Summary
Medicare Utilization ↗16,201
Medicare services
Top 1% in TX for critical care medicine
2,015
Unique beneficiaries
$35
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~853 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, mepolizumab, 1 mg | 12,101 | $23 | $53 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,390 | $95 | $193 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
642 | $48 | $94 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
400 | $57 | $110 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
291 | $21 | $41 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
188 | $69 | $136 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
185 | $91 | $179 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
116 | $4 | $20 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
113 | $61 | $119 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
107 | $123 | $251 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
79 | $89 | $176 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
74 | $43 | $82 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
71 | $26 | $51 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
69 | $45 | $85 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
61 | $95 | $183 |
| Electronic analysis of implanted neurostimulator with complex programming This procedure involves electronically analyzing an implanted neurostimulator generator and performing complex programming for a cranial nerve stimulator. |
52 | $41 | $80 |
| Sleep study with heart rate and breathing monitoring A sleep study that monitors heart rate, breathing patterns, and sleep duration. This test records physiological data while you sleep to assess your sleep quality and breathing function. |
50 | $28 | $49 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
49 | $10 | $21 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
41 | $31 | $58 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
39 | $114 | $269 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
26 | $85 | $191 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
24 | $87 | $170 |
| Bronchial irrigation and suction for cell collection This procedure uses an endoscope to flush and suction the lung airways in order to collect cells for testing. |
17 | $67 | $386 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
16 | $128 | $261 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$103,802
Total received (2018-2024)
Avg $14,829/year across 7 years
Top 3% in TX for critical care medicine
69
Companies
1,095
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$82,826 (79.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$20,181 (19.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$795 (0.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,089
2023
$4,953
2022
$10,077
2021
$17,361
2020
$31,147
2019
$35,071
2018
$2,105
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$44,078
GENZYME CORPORATION
$16,447
Mylan Specialty L.P.
$14,883
Regeneron Healthcare Solutions, Inc.
$8,313
AstraZeneca Pharmaceuticals LP
$6,694
Inspire Medical Systems, Inc.
$2,185
Actelion Pharmaceuticals US, Inc.
$1,960
JAZZ PHARMACEUTICALS INC.
$1,092
Genentech USA, Inc.
$960
Insmed, Inc.
$660
Boehringer Ingelheim Pharmaceuticals, Inc.
$639
Amgen Inc.
$372
Mallinckrodt Hospital Products Inc.
$340
Philips Electronics North America Corporation
$322
United Therapeutics Corporation
$318
Axsome Therapeutics, Inc.
$302
Grifols USA, LLC
$270
Allergan Inc.
$252
Janssen Pharmaceuticals, Inc
$252
HARMONY BIOSCIENCES LLC
$199
Jazz Pharmaceuticals Inc.
$189
Novartis Pharmaceuticals Corporation
$177
Harmony Biosciences LLC
$175
Merck Sharp & Dohme Corporation
$170
Pulmonx Corporation
$161
Optinose US, Inc.
$158
PFIZER INC.
$152
BAXTER HEALTHCARE
$118
Octapharma USA, Inc.
$117
Inogen, Inc.
$114
Ethicon US, LLC
$113
Allergan, Inc.
$96
OptiNose US, Inc.
$88
Shionogi Inc
$86
AbbVie Inc.
$74
Mallinckrodt LLC
$72
E.R. Squibb & Sons, L.L.C.
$68
Merck Sharp & Dohme LLC
$68
Philips North America LLC
$67
Electromed, Inc.
$60
ANI Pharmaceuticals, Inc.
$58
Baxter Healthcare
$49
NOVARTIS PHARMACEUTICALS CORPORATION
$48
Circassia Pharmaceuticals Inc
$47
SANOFI-AVENTIS U.S. LLC
$47
ABBVIE INC.
$46
Advanced Respiratory, Inc
$42
Teva Pharmaceuticals USA, Inc.
$40
PORTOLA PHARMACEUTICALS, INC.
$39
Tactile Systems Technology Inc
$35
Chiesi USA, Inc.
$33
CSL Behring
$33
Paratek Pharmaceuticals, Inc.
$33
INOGEN, INC.
$31
Vifor Pharma, Inc.
$31
Alexion Pharmaceuticals, Inc.
$30
Resmed Corp
$30
Bayer HealthCare Pharmaceuticals Inc.
$29
Avadel CNS Pharmaceuticals, LLC
$28
ZOLL Respicardia, Inc.
$28
Alcresta Therapeutics, Inc.
$28
Takeda Pharmaceuticals U.S.A., Inc.
$26
Harmony Biosciences Llc
$24
ADVANCED RESPIRATORY, INC
$21
Astellas Pharma US Inc
$19
Pharming Healthcare, Inc.
$18
Melinta Therapeutics, LLC
$17
Abbott Laboratories
$15
Gilead Sciences, Inc.
$14
Top 3 companies account for 72.6% of total payments
Associated products mentioned in payments ›
(2383) SleepUndivided · (7999) SRC Und · (8685) OEM Other · (8874) inCourage · (AK6) Vest Therapy · ACTHAR · AIRSENSE · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Adempas · Arikayce · BEVESPI AEROSPHERE · BEVYXXA · BREO · BREZTRI · BREZTRI AEROSPHERE · CARDIOMEMS · CHANTIX · CHARTIS CATHETER · CINQAIR · CLEVIPREX · CRESEMBA · CUTAQUIG · DALVANCE · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Dymista · ELIQUIS · Esbriet · FASENRA · Fetroja · Flexitouch Plus · Hillrom - Vest System Model 105 Home Care · INOGEN ONE G3 OXYGEN CONCENTRATOR · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · INSPIRE · InogenOne · Inspire Upper Airway Stimulation System · KENGREAL · KEYTRUDA · LUMRYZ · NUCALA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · PURIFIED CORTROPHIN GEL · Perforomist · ProAir Digihaler · Prolastin-C Liquid · RELIZORB · REMODULIN · RUCONEST · Renal - CRRT · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Sunosi · TAKHZYRO · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · Trilogy 100 · ULTOMIRIS · UPTRAVI · Vabomere · Veltassa · WAKIX · WINREVAIR · Wakix · Wellcentive Undiv · XARELTO · XOLAIR · XYREM · XYWAV · Xembify · Xhance · Xolair · Xyrem · YUPELRI · Yupelri · ZERBAXA · Zemaira · inCourage · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (80%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in critical care medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for critical care medicine in TX.
Equivalent to $641 per 100 Medicare services performed
Geographic Context
Critical care medicines within 10 mi
111
Per 100K population
2.3
County median income
$73,104
Nearest hospital
HOUSTON METHODIST WILLOWBROOK HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Puppala is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with speaking/promotional industry engagement in the top 3% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Puppala experienced with injection, mepolizumab, 1 mg?
Based on Medicare claims data, Dr. Puppala performed 12,101 injection, mepolizumab, 1 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Puppala receive payments from pharmaceutical companies?
Yes. Dr. Puppala received a total of $103,802 from 69 companies across 1,095 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Puppala's costs compare to other critical care medicines in Houston?
Dr. Puppala's average Medicare payment per service is $35. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Puppala) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Critical Care Medicines in Houston
Browse critical care medicines in Houston ranked by procedure volume and transparency data.
Highest volume
Top Critical Care Medicines in TX
Critical care medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Critical Care Medicines in TX
Which TX critical care medicines receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Mylan Specialty L.P. Payments to Doctors
See all physicians who received payments from Mylan Specialty L.P.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology